Nymox Pharmaceutical ratios data for the quarter ended Dec 2025. These financial ratios cover 33 quarters of results from Dec 2015 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| RatiosRatios | Dec2015 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Sep2024 | Dec2024 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||||||||||||
| Gross Margin | 73.08% | 20.00% | |||||||||||||||||||||||||||||||
| EBT Margin | -9,930.77% | -52,300.00% | |||||||||||||||||||||||||||||||
| EBIT Margin | -10,411.54% | -52,620.00% | |||||||||||||||||||||||||||||||
| EBITDA Margin | -10,403.85% | -52,580.00% | |||||||||||||||||||||||||||||||
| Operating Margin | -10,411.54% | -52,620.00% | |||||||||||||||||||||||||||||||
| Net Margin | -10,334.62% | -52,300.00% | |||||||||||||||||||||||||||||||
| FCF Margin | -6,973.08% | -43,380.00% | |||||||||||||||||||||||||||||||
| Efficiency | |||||||||||||||||||||||||||||||||
| Inventory AverageInventory Avg. | 0.03M | 0.02M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M | |||||||||||||||||||||
| Assets AverageAssets Avg. | 6.48M | 4.43M | 2.21M | 3.40M | 5.04M | 2.90M | 4.06M | 5.26M | 2.65M | 1.34M | 2.86M | 3.81M | 2.38M | 1.10M | 0.42M | 0.47M | 0.65M | 0.63M | 0.64M | 0.62M | |||||||||||||
| Equity AverageEquity Avg. | 4.55M | 2.44M | 0.19M | 18.69M | 20.29M | 1.07M | 2.35M | 3.15M | 0.54M | -0.95M | 0.42M | 1.50M | 0.15M | -1.14M | -2.34M | -2.39M | -2.54M | -4.73M | -6.54M | -8.04M | |||||||||||||
| Invested CapitalInvested Cap. | 3.45M | 2.51M | 0.33M | 5.01M | 2.03M | ||||||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | ||||||||||||||||||||||||||||
| Leverage & Solvency | |||||||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -21.66 | -526.20 | 0.00M | 0.00M | 0.00M | -147.80 | 139.42 | -692.50 | -109.90 | -46.09 | -194.12 | -10.37 | -9.16 | ||||||||||||||||||||
| Debt Ratio | 0.00 | 0.08 | 0.23 | 0.05 | 0.12 | ||||||||||||||||||||||||||||
| Times Interest Earned | -21.66 | -526.20 | 0.00M | 0.00M | 0.00M | -147.80 | 139.42 | -692.50 | -109.90 | -46.09 | -194.12 | -10.37 | -9.16 | ||||||||||||||||||||
| Valuation | |||||||||||||||||||||||||||||||||
| Price to SalesP/S | 0.00M | 0.00M | 0.00M | 0.01M | 0.04M | ||||||||||||||||||||||||||||
| Price to BookP/B | 45.44 | 115.65 | 4.56 | 90.14 | 26.17 | 101.45 | 16.86 | 45.37 | |||||||||||||||||||||||||
| Enterprise Value | 151.44M | 163.65M | 252.06M | 169.83M | 189.73M | 173.07M | 123.18M | 157.46M | 110.38M | 107.12M | 33.57M | 32.37M | 27.56M | 30.42M | 17.07M | 46.99M | 55.12M | 11.18M | 9.38M | 4.08M | |||||||||||||
| Market Capitalization | 156.68M | 166.65M | 252.83M | 175.20M | 193.34M | 173.07M | 123.18M | 160.60M | 111.21M | 107.79M | 37.64M | 35.07M | 28.96M | 30.78M | 17.20M | 47.07M | 55.19M | 11.22M | 9.45M | 4.08M | |||||||||||||
| Price to FCFP/FCF | 26.79 | ||||||||||||||||||||||||||||||||
| EV to FCF | 25.97 | ||||||||||||||||||||||||||||||||
| EV to CFO | 25.97 | ||||||||||||||||||||||||||||||||
| Return Ratios | |||||||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -10,411.54% | -52,620.00% | -15,390.00% | -40,035.48% | -234,380.00% | ||||||||||||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -300.28% | -497.07% | -5,496.43% | -826.57% | -380.92% | -650.68% | -522.25% | -340.89% | -1,452.38% | -1,943.39% | -767.11% | -2,410.14% | |||||||||||||||||||||
| Return on Assets [ROA]ROA | -203.26% | -291.35% | -483.64% | -364.92% | -232.83% | -398.83% | -310.45% | -223.44% | -473.63% | -1,132.71% | -345.03% | -211.35% | -275.95% | -261.55% | -1,259.34% | -1,036.60% | -1,364.81% | -1,306.63% | -1,239.44% | ||||||||||||||
| Return on Equity [ROE]ROE | -289.34% | -528.00% | -5,677.98% | -66.34% | -57.84% | -1,084.11% | -537.25% | -373.74% | -2,328.13% | -2,340.62% | -535.57% | -4,519.59% |
Pull Nymox Pharmaceutical's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NYMXF&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NYMXF", "statement": "Ratios", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NYMXF&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();